gip and glp 1 receptor agonist Tirzepatide's Unique Mechanism of Action Understand GLP-1/GIP Dual Agonist Tirzepatide
Description
At 24 weeks, the mean relative change from baseline in liver fat was a 42.9% reduction in the 1 mg group, a 57.0% reduction at 4 mg, an 81.4% reduction at 8 mg, and an 82.4% reduction at the 12 mg dose
EBioMedicine 93 , 104642 (2023)
References Bray GAPJ
Members must meet specific lifestyle modification requirements, BMI thresholds, and/or have certain co-morbid conditions that may qualify for GLP-1s
